IJERPH, Vol. 16, Pages 1779: Single Core Genome Sequencing for Detection of both Borrelia burgdorferi Sensu Lato and Relapsing Fever Borrelia Species
This study presented examples of base-calling DNA sequencing electropherograms routinely generated in a clinical diagnostic laboratory on DNA extracts of human blood specimens and ticks collected from human skin bites and from the environment. Since some of the tick samples tested were collected in Ireland, borrelial species or strains not known to exist in the United States were also detected by analysis of this 16S rRNA “core genome”. We recommend that hospital laboratories located in Lyme disease endemic areas begin to use a “core genome” sequencing test to routinely diagnose spirochetemia caused by various species of borreliae for timely management of patients at the early stage of infection.
Publication date: Available online 2 June 2020Source: European Journal of Obstetrics &Gynecology and Reproductive BiologyAuthor(s): Mona Bourg, Adeline Ruyssen-Witrand, Célia Bettiol, Jean Parinaud
On the heels of studies showing hydroxychloroquine doesn't help patients in the hospital with Covid-19, a new study -- the first of its kind -- shows the drug doesn't work to prevent infection with the virus, either.
The United States should have 100 million doses of one candidate coronavirus vaccine by the end of the year, Dr. Anthony Fauci, the director of the National Institute of Allergy and Infectious Diseases and a member of the White House Coronavirus Task Force, said Tuesday.
The Trump administration chose 5 companies as the most likely to produce a vaccine. The tally of new cases is rising in the U.S., partly because of expanded testing. Italy ends travel restrictions.
Researchers say that a malaria drug President Donald Trump took to try to prevent COVID-19 proved ineffective for that in the first large, high-quality study to test it in health workers and others closely exposed to people with the disease
The first carefully controlled trial of hydroxychloroquine given to people exposed to the coronavirus did not show any benefit.
U.S. President Donald Trump had no side effects from a two-week course of hydroxychloroquine, an anti-malaria drug that can cause heart problems, after using it as a preventive measure against the coronavirus, his White House physician said on Wednesday.
The Trump administration has selected five companies, including Moderna Inc, AstraZeneca Plc and Pfizer Inc, as the most likely candidates to produce a vaccine for the novel coronavirus, the New York Times reported on Wednesday, citing senior officials.
The malaria drug promoted by U.S. President Donald Trump as a treatment for COVID-19 was shown to be ineffective in preventing infection in people exposed to the coronavirus, according to a widely anticipated clinical trial released on Wednesday.
A new trial showed that the antimalarial drug hydroxychloroquine, touted repeated by the president, did not prevent healthy people from developing covid-19, the disease caused by the coronavirus.
More News: Arthritis | Borrelia | Databases & Libraries | Department of Health | Endemics | Environmental Health | Genetics | Hospitals | International Medicine & Public Health | Ireland Health | Laboratory Medicine | Lyme Disease | Politics | Rheumatology | Skin | Study | Tickborne Diseases | USA Health